

discarding a water soluble fraction of the first acidified extract and collecting the precipitate.

### **REMARKS**


The Examiner has required restriction to one of the following inventions under 35 U.S.C. 121: Group I, including Claims 1-11, drawn to a method for isolating a composition from the leaves of *Gymnema sylvestre*; Group II, including Claims 12-13, drawn to a composition obtained from the leaves of *Gymnema sylvestre*; Group III, including Claims 14-19, 21 or 23, drawn to a method of administering the composition for treating diabetic patients, impaired glucose tolerance, regenerating the pancreatic islets, increasing endogenous insulin levels in a patient or proinsulin in a patient; Group IV, including Claim 22, drawn to increasing endogenous lipase and amylase levels; Group V, including Claim 24, drawn to a method for increasing the production of c-peptide in a patient; and Group VI, including Claim 20, drawn to a method for lowering blood lipid, triglyceride, and free fatty acid levels.

Applicants elect with traverse to prosecute the invention of Group III, including Claims 14-19, 21, or 23, drawn to a method of administering the composition for treating diabetic patients; impaired glucose tolerance; regenerating the pancreatic islets; regenerating pancreatic beta cells; increasing endogenous insulin levels in a patient or proinsulin in a patient.

Several of the claims have been amended. Claims 14, 17-19, 21 and 23 have been amended to incorporate the subject matter of Claim 1. It is urged that there is a clear basis in the application as filed for the claims as amended.

Favorable consideration of the subject application is respectfully requested.

Respectfully submitted,

By:   
Ann W. Speckman  
Registration No. 31,881

Date: December 15, 1998  
LAW OFFICES OF ANN W. SPECKMAN  
2601 Elliott Avenue, Suite 4185  
Seattle, Washington 98121  
Attention: Ann W. Speckman  
Telephone: (206) 269-0565  
Docket No. 53000/1001